Curevac accelerates oncology strategy with acquisition of frame cancer therapeutics, adding novel antigen discovery platform

Acquisition extends curevac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigens tÜbingen, germany and amsterdam, netherlands / accesswire / june 8, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced its acquisition of frame cancer therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.
CVAC Ratings Summary
CVAC Quant Ranking